TMCnet News
Global Depression Therapeutics Report H2 2016 - Pipeline Review of 92 Companies & 177 Molecules - Research and MarketsResearch and Markets has announced the addition of the "Depression - Pipeline Review, H2 2016" report to their offering. Depression pipeline therapeutics constitutes close to 177 molecules. Out of which approximately 153 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Depression - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 25, 25, 1, 67, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 8 molecules, respectively. Furthermore, this eport also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/929k33/depression
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006411/en/ |